Merck & Company Inc
MRK · NYSE82.09
82.09
USD1.201.48%Data
Ticker
Titolo
Fonte
RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants - CNBC
CNBC
Merck made $3B+ offer for MoonLake earlier this year - report
SeekingAlpha
Merck KGaA to buy Springworks for $3.9 billion
SeekingAlpha
SpringWorks jumps as Merck KGaA reportedly nears $3.5B buyout deal
SeekingAlpha
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
MarketWatch
SpringWorks Therapeutics jumps on report of Merck KGaA takeover talks
SeekingAlpha
🇺🇸EARNINGS THIS WEEK: • ALPHABET $GOOGL • AMAZON $AMZN • AMD $AMD • ARM HOLDINGS $ARM • QUALCOMM $QCOM • PALANTIR $PLTR • FORTINET $FTNT • SNAP $SNAP • ROBLOX $RBLX • WALT DISNEY $DIS • PAYPAL $PYPL • ELI LILLY $LLY • PFIZER $PFE • MERCK $MRK • NOVO NORDISK $NVO… https://t.co/n8VluKA3Gy https://t.co/NBsP246CAc
Incyte seesaws on report of potential Merck takeover interest
SeekingAlpha
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
MarketWatch
M&A deals roundup: Merck, Seadrill, Kraft Heinz, Spirit Airlines and more
SeekingAlpha
Merck buys Modifi for $30M plus up to $1.3B in potential payments
SeekingAlpha
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval - CNBC
CNBC
Merck says trial of combination treatment for colon cancer failed to meet main goal
MarketWatch
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
MarketWatch
Summit Therapeutics’ stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
MarketWatch
Merck to buy experimental drug targeting B-cell diseases for up to $1.3 billion
MarketWatch
Merck discontinues late-stage trial of experimental lung cancer treatment after high number of adverse events
MarketWatch
Merck shares drop 10% as pharma giant scraps trial of promising cancer drug
MarketWatch
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections - CNBC
CNBC
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer - CNBC
CNBC
Merck to buy eye-care startup EyeBio for up to $3B - report
SeekingAlpha
Cramer’s week ahead: Earnings from Tesla, Merck and Big Tech
CNBC
FDA approves Merck's drug for rare, deadly lung condition
CNBC
Harpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Merck
SeekingAlpha
Harpoon Therapeutics ticks higher after HSR waiting period for Merck deal expires
SeekingAlpha
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen
MarketWatch
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
MarketWatch
Elanco’s stock heads for 18-month high as company sells aqua business to Merck for $1.3 billion in cash
MarketWatch
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
CNBC
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs - CNBC
CNBC
Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics
MarketWatch
Merck in talks to acquire Harpoon Therapeutics for around $700M - Bloomberg
SeekingAlpha
Merck KGaA suffers major blow as MS drug fails in late-stage trials - Reuters
Reuters
Merck to acquire Caraway Therapeutics for $610M
SeekingAlpha
Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth
CNBC
Earnings Results: Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth
MarketWatch
Dow Jones Newswires: Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
MarketWatch
Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancer
MarketWatch
FAQ
Cosa stai aspettando?Inizia a fare profitto oggi
Strumenti
Mercati
Più
Risorse
Confronta
App mobile Profit
Scopri il mondo della finanza nel tuo taschino
©
2025
Tutti i diritti riservati